153 related articles for article (PubMed ID: 27697749)
1. ENHANCE-(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease.
Creary S; Chisolm DJ; O'Brien SH
JMIR Res Protoc; 2016 Oct; 5(4):e193. PubMed ID: 27697749
[TBL] [Abstract][Full Text] [Related]
2. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
4. Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study.
Hankins JS; Shah N; DiMartino L; Brambilla D; Fernandez ME; Gibson RW; Gordeuk VR; Lottenberg R; Kutlar A; Melvin C; Simon J; Wun T; Treadwell M; Calhoun C; Baumann A; Potter MB; Klesges L; Bosworth H;
JMIR Res Protoc; 2020 Jul; 9(7):e16319. PubMed ID: 32442144
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
Makubi A; Sasi P; Ngaeje M; Novelli EM; Mmbando BP; Gladwin MT; Makani J
BMC Med Res Methodol; 2016 Oct; 16(1):140. PubMed ID: 27756209
[TBL] [Abstract][Full Text] [Related]
6. Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach.
Alberts NM; Badawy SM; Hodges J; Estepp JH; Nwosu C; Khan H; Smeltzer MP; Homayouni R; Norell S; Klesges L; Porter JS; Hankins JS
JMIR Mhealth Uhealth; 2020 May; 8(5):e14884. PubMed ID: 32383683
[TBL] [Abstract][Full Text] [Related]
7. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
[TBL] [Abstract][Full Text] [Related]
8. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
[TBL] [Abstract][Full Text] [Related]
9. Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.
Green NS; Manwani D; Matos S; Hicks A; Soto L; Castillo Y; Ireland K; Stennett Y; Findley S; Jia H; Smaldone A
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643377
[TBL] [Abstract][Full Text] [Related]
10. Adherence to Hydroxyurea and Patients' Perceptions of Sickle Cell Disease and Hydroxyurea: A Cross-Sectional Study.
Madkhali MA; Abusageah F; Hakami F; Zogel B; Hakami KM; Alfaifi S; Alhazmi E; Zaalah S; Trabi S; Alhazmi AH; Mohrag M; Malhan H
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256385
[No Abstract] [Full Text] [Related]
11. Using a Mobile Health Intervention (DOT Selfie) With Transfer of Social Bundle Incentives to Increase Treatment Adherence in Tuberculosis Patients in Uganda: Protocol for a Randomized Controlled Trial.
Sekandi JN; Onuoha NA; Buregyeya E; Zalwango S; Kaggwa PE; Nakkonde D; Kakaire R; Atuyambe L; Whalen CC; Dobbin KK
JMIR Res Protoc; 2021 Jan; 10(1):e18029. PubMed ID: 32990629
[TBL] [Abstract][Full Text] [Related]
12. Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study.
Inoue S; Kodjebacheva G; Scherrer T; Rice G; Grigorian M; Blankenship J; Onwuzurike N
Int J Hematol; 2016 Aug; 104(2):200-7. PubMed ID: 27225236
[TBL] [Abstract][Full Text] [Related]
13. Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study.
Badawy SM; DiMartino L; Brambilla D; Klesges L; Baumann A; Burns E; DeMartino T; Jacobs S; Khan H; Nwosu C; Shah N; Hankins JS;
JMIR Form Res; 2022 Oct; 6(10):e41415. PubMed ID: 36240004
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life and Adherence to Hydroxyurea and Other Disease-Modifying Therapies among Individuals with Sickle Cell Disease: A Systematic Review.
Yang M; Elmuti L; Badawy SM
Biomed Res Int; 2022; 2022():2122056. PubMed ID: 35898672
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
16. Mobile health intervention for youth with sickle cell disease: Impact on adherence, disease knowledge, and quality of life.
Anderson LM; Leonard S; Jonassaint J; Lunyera J; Bonner M; Shah N
Pediatr Blood Cancer; 2018 Aug; 65(8):e27081. PubMed ID: 29693797
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
[TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH
Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea: Pattern of Use, Patient Adherence, and Safety Profile in Patients with Sickle Cell Disease in Oman.
Jose J; Elsadek RA; Jimmy B; George P
Oman Med J; 2019 Jul; 34(4):327-335. PubMed ID: 31360322
[TBL] [Abstract][Full Text] [Related]
20. A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease.
Hankins JS; Brambilla D; Potter MB; Kutlar A; Gibson R; King AA; Baumann AA; Melvin C; Gordeuk VR; Hsu LL; Nwosu C; Porter JS; Alberts NM; Badawy SM; Simon J; Glassberg JA; Lottenberg R; DiMartino L; Jacobs S; Fernandez ME; Bosworth HB; Klesges LM; Shah N
Blood Adv; 2023 Dec; 7(23):7190-7201. PubMed ID: 37738155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
